Introduced

Passed House

Passed Senate

Became law

Adjourned sine die. The bill was pending when the session ended, so it did not pass.

Last action · February 26, 2025

To Banking & Insurance (H)

Introduced February 18, 2025

House

Adjourned Sine Die

2025 Regular Session

HB683

AN ACT relating to coverage for the treatment of postpartum mood disorders.

Create a new section of Subtitle 17A of KRS Chapter 304 to require health benefit plans to provide coverage for FDA-approved prescription drugs for the treatment of postpartum mood disorders; allow the suspension of the coverage requirement for FDA-approved prescription drugs for the treatment of postpartum mood disorders under qualified health plans if cost defrayment required by the state; amend KRS 205.522, 205.6485, 18A.225, and 164.2871 to require Medicaid, Kentucky Children's Health Insurance Program, the…

Drugs and Medicines Education, Higher Effective Dates, Delayed Insurance, Health Mental Health Reproductive Issues State Employees Women Medicaid Children and Minors Local Mandate State Employee Health Plan Mandate Actuarial Analysis Health Benefit Plan Mandate

Read the full text Kentucky Legislature LegiScan

AI-generated. Always verify with primary sources

Plain-language summary

Beta

This bill would require most Kentucky health insurance plans to cover FDA-approved prescription drugs used to treat postpartum mood disorders, such as postpartum depression, starting January 1, 2026. It applies to private health plans, Medicaid, the Kentucky Children's Health Insurance Program, the state employee health plan, and health plans offered by public colleges and universities to their employees. Who it may affect: new mothers and birthing parents covered by insurance in Kentucky, Medicaid recipients, state employees, and employees of public colleges and universities.

Open official bill text (PDF)·Report a problem with the summary